GLP1 and cancer: friend or foe? in: Endocrine-Related Cancer Volume 19 Issue 5 (2012)
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. - Abstract - Europe PMC
GLP-1 actions and target organs. GLP-1, through its receptor GLP-1R,... | Download Scientific Diagram
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in: Journal of Endocrinology Volume 236 Issue 1 (2018)
Schematic on GLP-1 mediated insulin secretion in the b-cell. GLUT1/2:... | Download Scientific Diagram
Schematic on the nutrient-induced stimulation of GLP-1 secretion in the... | Download Scientific Diagram
Cells | Free Full-Text | The Role of cAMP in Beta Cell Stimulus–Secretion and Intercellular Coupling | HTML
References in Progress and challenges in anti-obesity pharmacotherapy - The Lancet Diabetes & Endocrinology
The Cardiovascular Biology of Glucagon-like Peptide-1 - ScienceDirect
Pharmaceuticals | Free Full-Text | Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes | HTML
Frontiers | DPP-4 Inhibition and the Path to Clinical Proof | Endocrinology
The privileged position of glp-1 in diabetic nephropathy - MedCrave online
Figure 2 from Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists | Semantic Scholar
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 - ScienceDirect
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar | Journal of the American College of Cardiology
Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists - Diabetes Research and Clinical Practice
Frontiers | Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes | Endocrinology
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology
Metformin?action. Glp-1 mechanism of action. pancreas, stomach and brain as glucagon-like peptide target organs. | CanStock
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors | Circulation
